INS and type 2 diabetes mellitus: Although current treatments have proven to be successful in improving glycemic control in T2D patients, the existence of variations in the effectiveness of therapies and their tolerance among patients leads to a clinical need for new diabetic therapies that not only offer glucose-lowering effects but also address the underlying β-cell failure by preserving functional β-cell mass while improving insulin responsiveness.